Exscientia
Oxford · Artificial Intelligence, Biotechnology, Data And Analytics
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small mo
Key facts
- Headquarters
- Oxford
- Employees
- 455
- Industries
- Artificial Intelligence, Biotechnology, Data And Analytics
- Status
- Private
- Website
- www.exscientia.ai
- Company page
Recent activity at Exscientia
- : Exscientia Announces Strategic Partnership with Google Cloud Worth Over $250 Million
- : Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration
- : Recursion and Exscientia Enter Definitive Agreement to Combine Forces in Drug Discovery
- : Exscientia Appoints John P. Overington as Chief Technology Officer and Marie-Louise Fjällskog, M.D., Ph.D., as Interim Chief Medical Officer
- : Exscientia Announces Closing Of $510.4 Million Aggregate Financing, Consisting Of $350.4 Million Upsized Initial Public Offering With Full Exercise Of Underwriters’ Option To Purchase Additional Adss And $160.0 Million Concurrent Private Placement
- : Exscientia Completes $100 million Series C Financing Round With BlackRock Funds
Exscientia funding history
| Date | Round | Amount |
|---|---|---|
| Oct 2021 | Post-IPO Equity | $510.4M |
| Mar 2021 | Series C | $100.0M |
Leadership
- Marie-Louise Fjällskog, M.D., Ph.D., Chief Medical Officer
- John P. Overington, Ph.D., Chief Technology Officer
Verified email and direct lines for Exscientia’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Exscientia in the news
- Exscientia to start world-first trials of AI-designed immuno-oncology drug - Clinical Trials Arena (Apr 09, 2021)
- AI drug discovery space consolidates with $688M Recursion and Exscientia merger - Drug Discovery & Development (Aug 08, 2024)
- AI drug developers Recursion, Exscientia to merge - STAT (Aug 08, 2024)
- Recursion to absorb Exscientia in ‘techbio’ deal - BioPharma Dive (Aug 08, 2024)
- After a tough year, Exscientia folds into Recursion to create an AI superpower - Fierce Biotech (Aug 08, 2024)
- AI biotechs Exscientia and Recursion agree $688m merger - pharmaphorum (Aug 08, 2024)
- Pipeline Pruning: Exscientia Cuts Programs to Sharpen Precision Oncology Focus - Genetic Engineering and Biotechnology News (Dec 22, 2023)
- Sumitomo Dainippon Pharma, Exscientia advance AI drug candidate - Pharmaceutical Technology (Jan 30, 2020)
Companies similar to Exscientia
- IMPLICITY · Artificial Intelligence, Biotechnology, Data And Analytics, Health Care, Science And Engineering, Software
- Nucleai · Artificial Intelligence, Biotechnology, Data And Analytics, Health Care, Science And Engineering, Software
- Zephyr AI, Inc. · Artificial Intelligence, Biotechnology, Data And Analytics, Health Care, Science And Engineering, Software
- Aidoc · Artificial Intelligence, Data And Analytics, Health Care, Science And Engineering, Software
- Biofourmis · Artificial Intelligence, Biotechnology, Data And Analytics, Health Care, Software
About Exscientia: questions and answers
What does Exscientia do?
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small mo
Where is Exscientia headquartered?
Exscientia is headquartered in Oxford.
How many employees does Exscientia have?
Exscientia has about 455 employees.
Has Exscientia raised funding?
Yes. Fundz has recorded 2 funding events for Exscientia. The most recent, Post-IPO Equity of $510.4M, was in Oct 2021.
What is the latest news on Exscientia?
On Nov 14, 2024, Exscientia Announces Strategic Partnership with Google Cloud Worth Over $250 Million
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy